AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29176494 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancreatic enzyme replacement therapy (PERT) dosing between 6 and 12 months (mean 1842 LU/kg per meal, range: 313-3612)
Number of subjects: 205
Study 29176494 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of proton pump inhibitors (PPIs) exclusively
Number of subjects: 205
Study 29176494 — intervention group
Group type: COMPARATOR
Intervention: Higher PERT dosing strategy
Number of subjects: 205
Study 29176887 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-Time PCR (qPCR) testing for Chagas disease
Number of subjects: 302
Study 29176887 — intervention group
Group type: COMPARATOR
Intervention: Retesting of clinical samples from Bolivian laboratory
Number of subjects: 302
Study 29177052 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 1 diabetes with eGFR <60 mL/min/1.73 m²
Number of subjects: 43
Study 29177052 — intervention group
Group type: COMPARATOR
Intervention: Type 1 diabetes without diabetic kidney disease
Number of subjects: 43
Study 29177059 — intervention group
Group type: EXPERIMENTAL
Intervention: STEMI in men
Number of subjects: 51725
Study 29177059 — intervention group
Group type: EXPERIMENTAL
Intervention: STEMI in women
Number of subjects: 51725
Study 29177059 — intervention group
Group type: EXPERIMENTAL
Intervention: NSTEMI in men
Number of subjects: 51725
Study 29177059 — intervention group
Group type: EXPERIMENTAL
Intervention: NSTEMI in women
Number of subjects: 51725
Study 29177059 — intervention group
Group type: EXPERIMENTAL
Intervention: STEMI in women <60 years
Number of subjects: 51725
Study 29177059 — intervention group
Group type: EXPERIMENTAL
Intervention: NSTEMI in women <60 years
Number of subjects: 51725
Study 29177059 — intervention group
Group type: EXPERIMENTAL
Intervention: STEMI in men <60 years
Number of subjects: 51725
Study 29177059 — intervention group
Group type: EXPERIMENTAL
Intervention: NSTEMI in men <60 years
Number of subjects: 51725
Study 29177061 — intervention group
Group type: COMPARATOR
Intervention: General practitioners (GPs)
Number of subjects: 241
Study 29177061 — intervention group
Group type: COMPARATOR
Intervention: Rheumatologists
Number of subjects: 241
Study 29177061 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients
Number of subjects: 241
Study 29177070 — intervention group
Group type: EXPERIMENTAL
Intervention: MIS416 treatment for 12 weeks
Number of subjects: 11
Study 29177070 — intervention group
Group type: EXPERIMENTAL
Intervention: MIS416 treatment
Number of subjects: 11
Study 29177094 — intervention group
Group type: EXPERIMENTAL
Intervention: MAGE-A3 immunotherapeutic combined with dacarbazine (up to 24 doses of MAGE-A3 immunotherapeutic and eight doses of dacarbazine)
Number of subjects: 48
Study 29177094 — intervention group
Group type: EXPERIMENTAL
Intervention: MAGE-A3 immunotherapeutic
Number of subjects: 48
Study 29177452 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based educational intervention including four educational sessions over 4 weeks and six 30-min class discussions over 3 months.
Number of subjects: 456
Study 29177452 — intervention group
Group type: COMPARATOR
Intervention: Control group observed general sex education provided by the school.
Number of subjects: 456
Study 29177471 — intervention group
Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass surgery
Number of subjects: 82
Study 29177471 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline subcutaneous adipocyte volume
Number of subjects: 82
Study 29177471 — intervention group
Group type: EXPERIMENTAL
Intervention: WAT COL4A1 expression
Number of subjects: 82
Study 29177486 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP-1 0.7 pmol/kg/min
Number of subjects: 0
Study 29177486 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP-1 1.2 pmol/kg/min
Number of subjects: 0
Study 29177486 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP-1 and ROSE-010 (in vitro)
Number of subjects: 0
Study 29177486 — intervention group
Group type: COMPARATOR
Intervention: Control (saline infusion)
Number of subjects: 0
Study 29177645 — intervention group
Group type: EXPERIMENTAL
Intervention: Ledipasvir-Sofosbuvir for 8 weeks
Number of subjects: 126
Study 29177699 — intervention group
Group type: EXPERIMENTAL
Intervention: BI 409306 at 25 mg
Number of subjects: 40
Study 29177699 — intervention group
Group type: EXPERIMENTAL
Intervention: BI 409306 at 50 mg
Number of subjects: 40
Study 29177699 — intervention group
Group type: EXPERIMENTAL
Intervention: BI 409306 at 100 mg
Number of subjects: 40
Study 29177699 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 29177699 — intervention group
Group type: EXPERIMENTAL
Intervention: BI 409306
Number of subjects: 40
Study 29177953 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine plus sirolimus
Number of subjects: 28
Study 29178102 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorouracil-based chemotherapy
Number of subjects: 53
Study 29178583 — intervention group
Group type: EXPERIMENTAL
Intervention: Bariatric surgery (vertical gastroplasty, gastric banding, or gastric bypass)
Number of subjects: 2018
Study 29178583 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 2018
Study 29178583 — intervention group
Group type: EXPERIMENTAL
Intervention: Bariatric surgery
Number of subjects: 2018
Study 29178600 — intervention group
Group type: EXPERIMENTAL
Intervention: Norepinephrine stimulation of in vitro BAT activity in adipocytes derived from human BAT.
Number of subjects: 16
Study 29178600 — intervention group
Group type: EXPERIMENTAL
Intervention: UCP1 mRNA expression in human BAT biopsies.
Number of subjects: 16
Study 29178600 — intervention group
Group type: EXPERIMENTAL
Intervention: ZIC1 mRNA expression in human BAT biopsies.
Number of subjects: 16
Study 29178600 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of UCP1 mRNA with age and BMI.
Number of subjects: 16
Study 29178600 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of ZIC1 mRNA with age and BMI.
Number of subjects: 16
Study 29178853 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose computed tomography (LDCT) screening
Number of subjects: 1570
Study 29178853 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of pleural plaques
Number of subjects: 1570
Study 29178853 — intervention group
Group type: EXPERIMENTAL
Intervention: Asbestos exposure
Number of subjects: 1570
Study 29179674 — intervention group
Group type: EXPERIMENTAL
Intervention: suPAR levels ≥3.00 ng/ml
Number of subjects: 120
Study 29179674 — intervention group
Group type: EXPERIMENTAL
Intervention: Older age
Number of subjects: 120
Study 29179674 — intervention group
Group type: EXPERIMENTAL
Intervention: suPAR
Number of subjects: 120
Study 29179674 — intervention group
Group type: COMPARATOR
Intervention: Age alone
Number of subjects: 120
Study 29179674 — intervention group
Group type: EXPERIMENTAL
Intervention: Age + suPAR
Number of subjects: 120
Study 29179681 — intervention group
Group type: EXPERIMENTAL
Intervention: Low flow extracorporeal CO (Abylcap®)
Number of subjects: 0
Study 29179731 — intervention group
Group type: EXPERIMENTAL
Intervention: TACT trial
Number of subjects: 3151
Study 29179731 — intervention group
Group type: COMPARATOR
Intervention: NCDR
Number of subjects: 3151
Study 29179748 — intervention group
Group type: EXPERIMENTAL
Intervention: Thresholding analysis for quantification of bone marrow inflammatory edema
Number of subjects: 41
Study 29179748 — intervention group
Group type: EXPERIMENTAL
Intervention: Thresholding analysis for the spine
Number of subjects: 41
Study 29179748 — intervention group
Group type: EXPERIMENTAL
Intervention: Thresholding analysis for the SI joints
Number of subjects: 41
Study 29179748 — intervention group
Group type: COMPARATOR
Intervention: SPARCC scoring system
Number of subjects: 41
Study 29179751 — intervention group
Group type: EXPERIMENTAL
Intervention: Proton therapy (45-50.4 GyE in 1.8 GyE fractions 5-6 times per week)
Number of subjects: 25
Study 29179751 — intervention group
Group type: EXPERIMENTAL
Intervention: Proton therapy
Number of subjects: 25
Study 29179770 — intervention group
Group type: EXPERIMENTAL
Intervention: Fistula repair
Number of subjects: 148
Study 29180344 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga
Number of subjects: 300
Study 29180344 — intervention group
Group type: EXPERIMENTAL
Intervention: Memory compensation training
Number of subjects: 300
Study 29180344 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized cognitive training
Number of subjects: 300
Study 29180344 — intervention group
Group type: EXPERIMENTAL
Intervention: Support groups
Number of subjects: 300
Study 29180344 — intervention group
Group type: EXPERIMENTAL
Intervention: Wellness education
Number of subjects: 300
Study 29180344 — intervention group
Group type: COMPARATOR
Intervention: Other four interventions withheld
Number of subjects: 300
Study 29180345 — intervention group
Group type: EXPERIMENTAL
Intervention: In-person MBI
Number of subjects: 0
Study 29180345 — intervention group
Group type: EXPERIMENTAL
Intervention: eHealth MBI
Number of subjects: 0
Study 29180545 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical pharmacist-led medication therapy management (MTM) service enhanced by a clinical decision support system (CDSS) and pharmacogenomics (PGx) testing.
Number of subjects: 0
Study 29180545 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical pharmacist-led MTM Plus service
Number of subjects: 0
Study 29180545 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacogenomics (PGx) testing
Number of subjects: 0
Study 29180633 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive therapy using patient-specific tumor dynamics
Number of subjects: 11
Study 29180633 — intervention group
Group type: COMPARATOR
Intervention: Standard abiraterone dosing
Number of subjects: 11
Study 29181002 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 0
Study 29181002 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane
Number of subjects: 0
Study 29181002 — intervention group
Group type: EXPERIMENTAL
Intervention: Both Propofol and Isoflurane
Number of subjects: 0
Study 29181489 — intervention group
Group type: EXPERIMENTAL
Intervention: CNP520 (a beta-site-amyloid precursor protein-cleaving enzyme inhibitor)
Number of subjects: 0
Study 29181489 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 29181490 — intervention group
Group type: EXPERIMENTAL
Intervention: Lanabecestat (AZD3293/LY3314814)
Number of subjects: 0
Study 29181491 — intervention group
Group type: EXPERIMENTAL
Intervention: Aducanumab (BIIB037), a human monoclonal antibody targeting aggregated forms of Aβ, administered in an ongoing phase Ib trial (PRIME).
Number of subjects: 196
Study 29181491 — intervention group
Group type: EXPERIMENTAL
Intervention: Aducanumab (BIIB037) in patients with prodromal or mild AD.
Number of subjects: 196
Study 29181491 — intervention group
Group type: EXPERIMENTAL
Intervention: Aducanumab (BIIB037) in ApoE ε4 carriers.
Number of subjects: 196
Study 29181702 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (UDCA) therapy
Number of subjects: 474
Study 29181702 — intervention group
Group type: EXPERIMENTAL
Intervention: UK-PBC risk score
Number of subjects: 474
Study 29181702 — intervention group
Group type: EXPERIMENTAL
Intervention: Globe score
Number of subjects: 474
Study 29181829 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term endurance training (150 min/week moderate or 75 min/week intense exercise)
Number of subjects: 36
Study 29182496 — intervention group
Group type: EXPERIMENTAL
Intervention: BGJ398 125 mg once daily for 21 days, then 7 days off (28-day cycles)
Number of subjects: 61
Study 29182496 — intervention group
Group type: EXPERIMENTAL
Intervention: BGJ398
Number of subjects: 61
Study 29182729 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioids (morphine equivalent dose given 24 hours prior to extubation)
Number of subjects: 56
Study 29182729 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory airway obstruction (MEF50/MIF50 ≥ 1) assessed by bedside spirometry
Number of subjects: 56
Study 29182737 — intervention group
Group type: EXPERIMENTAL
Intervention: Women with PCOS
Number of subjects: 475
Study 29182737 — intervention group
Group type: COMPARATOR
Intervention: Women without PCOS (comparison group)
Number of subjects: 475
Study 29182737 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-efficacy of dietary behaviors
Number of subjects: 475
Study 29182949 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquified petroleum gas (LPG) cookstove intervention
Number of subjects: 0
Study 29183318 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical pathways (CPWs) for COPD implemented in experimental groups
Number of subjects: 4
Study 29183318 — intervention group
Group type: COMPARATOR
Intervention: Control groups (no CPWs implemented)
Number of subjects: 4
Study 29183318 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthcare utilization measures (hospital admission rates, hospital length of stay, GP visits)
Number of subjects: 4
Study 29183337 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic respiration-synchronized couch motion
Number of subjects: 100
Study 29183337 — intervention group
Group type: COMPARATOR
Intervention: Static segments
Number of subjects: 100
Study 29183360 — intervention group
Group type: EXPERIMENTAL
Intervention: Rounded percentiles
Number of subjects: 5836
Study 29183360 — intervention group
Group type: COMPARATOR
Intervention: Z-scores
Number of subjects: 5836
Study 29183379 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot-assisted gait (RAG)
Number of subjects: 30
Study 29183379 — intervention group
Group type: COMPARATOR
Intervention: Free gait without robot assistance (FG)
Number of subjects: 30
Study 29183379 — intervention group
Group type: COMPARATOR
Intervention: Robot-assisted gait with zero torque (RAG-Z)
Number of subjects: 30
Study 29183868 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based HIV testing with remote video-based counseling
Number of subjects: 200
Study 29183868 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving one HIV self-testing kit and reporting results via website
Number of subjects: 200
Study 29183928 — intervention group
Group type: EXPERIMENTAL
Intervention: Normothermic machine perfusion of the liver (NMP-L) following a period of static cold storage.
Number of subjects: 0
Study 29183960 — intervention group
Group type: EXPERIMENTAL
Intervention: Radium-223 55 kBq/kg intravenously every 4 weeks × 6
Number of subjects: 184
Study 29183960 — intervention group
Group type: EXPERIMENTAL
Intervention: Radium-223
Number of subjects: 184
Study 29184049 — intervention group
Group type: EXPERIMENTAL
Intervention: Diaphragmatic electrical activity (EA) measurement before extubation
Number of subjects: 21
Study 29184532 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with new distant lesions (n=16, 14%)
Number of subjects: 115
Study 29184532 — intervention group
Group type: COMPARATOR
Intervention: Patients with new local lesions (n=99, 86%)
Number of subjects: 115
Study 29184537 — intervention group
Group type: EXPERIMENTAL
Intervention: VSL#3 probiotics
Number of subjects: 80
Study 29184537 — intervention group
Group type: COMPARATOR
Intervention: Control group (no probiotics)
Number of subjects: 80
Study 29184781 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy
Number of subjects: 0
Study 29184781 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiation with coordinated combined chemotherapy
Number of subjects: 0
Study 29185021 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical training and standardised management guidelines (Group C)
Number of subjects: 209
Study 29185021 — intervention group
Group type: COMPARATOR
Intervention: Surgical training and experience (Group A)
Number of subjects: 209
Study 29185021 — intervention group
Group type: COMPARATOR
Intervention: Plastic surgeons (Group B)
Number of subjects: 209
Study 29185557 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose IV alteplase (0.6 mg/kg)
Number of subjects: 3139
Study 29185557 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose IV alteplase (0.9 mg/kg)
Number of subjects: 3139
Study 29185557 — intervention group
Group type: EXPERIMENTAL
Intervention: Seizures
Number of subjects: 3139
Study 29185786 — intervention group
Group type: EXPERIMENTAL
Intervention: Low exposure desvenlafaxine (20, 30, or 35 mg/day based on baseline weight)
Number of subjects: 363
Study 29185786 — intervention group
Group type: EXPERIMENTAL
Intervention: High exposure desvenlafaxine (25, 35, or 50 mg/day based on baseline weight)
Number of subjects: 363
Study 29185786 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 363
Study 29186375 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive mitral valve surgery (MICS)
Number of subjects: 256
Study 29186458 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-days-a-week antiretroviral regimen
Number of subjects: 100
Study 29187226 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational video on informed consent process
Number of subjects: 30
Study 29187343 — intervention group
Group type: EXPERIMENTAL
Intervention: eHealth application for self-reported SRIIPS
Number of subjects: 28
Study 29187390 — intervention group
Group type: EXPERIMENTAL
Intervention: Obstructive sleep apnea (OSA)
Number of subjects: 1557
Study 29187390 — intervention group
Group type: EXPERIMENTAL
Intervention: Central sleep apnea (CSA)
Number of subjects: 1557
Study 29187390 — intervention group
Group type: EXPERIMENTAL
Intervention: Coexisting obstructive and central sleep apnea (OSA-CSA)
Number of subjects: 1557
Study 29187390 — intervention group
Group type: EXPERIMENTAL
Intervention: Periodic breathing (Cheyne-Stokes respiration)
Number of subjects: 1557
Study 29187390 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk factors for CSA vs OSA
Number of subjects: 1557
Study 29187850 — intervention group
Group type: EXPERIMENTAL
Intervention: Roux-en-Y bariatric surgery
Number of subjects: 37
Study 29188387 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabeprazole 10 mg b.i.d.
Number of subjects: 517
Study 29188387 — intervention group
Group type: COMPARATOR
Intervention: Rabeprazole 10 mg q.d.
Number of subjects: 517
Study 29188408 — intervention group
Group type: EXPERIMENTAL
Intervention: Demcizumab (5 mg/kg)
Number of subjects: 46
Study 29188408 — intervention group
Group type: EXPERIMENTAL
Intervention: Demcizumab (2.5, 5.0, and 7.5 mg/kg)
Number of subjects: 46
Study 29188408 — intervention group
Group type: EXPERIMENTAL
Intervention: Truncated regimen of demcizumab
Number of subjects: 46
Study 29188408 — intervention group
Group type: EXPERIMENTAL
Intervention: Demcizumab (5 mg/kg q3-weekly ×4)
Number of subjects: 46
Study 29188469 — intervention group
Group type: EXPERIMENTAL
Intervention: Merestinib (type II MET kinase inhibitor)
Number of subjects: 0
Study 29188469 — intervention group
Group type: EXPERIMENTAL
Intervention: Emibetuzumab (bivalent anti-MET antibody)
Number of subjects: 0
Study 29188469 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Merestinib and Emibetuzumab
Number of subjects: 0
Study 29188734 — intervention group
Group type: EXPERIMENTAL
Intervention: Current and lifetime DSM-IV diagnoses of axis-I (psychiatric disorders) and axis-II (personality disorders) assessed using structured clinical interviews (SCID-I and -II)
Number of subjects: 83
Study 29188734 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-rated psychiatric symptoms evaluated via the Symptom Check List-90 (SCL-90), Beck Depression Inventory, and Dissociative Experiences Scale (DES)
Number of subjects: 83
Study 29189665 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic drug monitoring (TDM) of busulfan
Number of subjects: 18
Study 29189665 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial busulfan dose based on age/weight
Number of subjects: 18
Study 29189665 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality control (QC) measurements
Number of subjects: 18
Study 29189665 — intervention group
Group type: EXPERIMENTAL
Intervention: Storage at -80°C
Number of subjects: 18
Study 29189665 — intervention group
Group type: COMPARATOR
Intervention: Cross-validation of analytical methods
Number of subjects: 18
Study 29189677 — intervention group
Group type: EXPERIMENTAL
Intervention: lopinavir/ritonavir-based ART
Number of subjects: 0
Study 29189677 — intervention group
Group type: COMPARATOR
Intervention: nevirapine-based ART
Number of subjects: 0
Study 29189950 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral care program using a foam stick (Period 1)
Number of subjects: 2030
Study 29189950 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral care program using a foam stick and tooth brushing with aspiration (Period 2)
Number of subjects: 2030
Study 29189950 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost assessment of the oral care program
Number of subjects: 2030
Study 29190340 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time continuous glucose monitoring (CGM)
Number of subjects: 11
Study 29190340 — intervention group
Group type: COMPARATOR
Intervention: Control group (nondiabetic participants)
Number of subjects: 11
Study 29190707 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypofractionated stereotactic boost (18 Gy, 3x6Gy) after conventional radiotherapy (46 Gy by IMRT or 3D conformal radiotherapy)
Number of subjects: 76
Study 29190925 — intervention group
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel plus S-1
Number of subjects: 0
Study 29191334 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment for secondary mitral regurgitation
Number of subjects: 0
Study 29191581 — intervention group
Group type: EXPERIMENTAL
Intervention: HLA-A2 positive patients
Number of subjects: 545
Study 29191581 — intervention group
Group type: COMPARATOR
Intervention: HLA-A2 negative patients
Number of subjects: 545
Study 29191581 — intervention group
Group type: EXPERIMENTAL
Intervention: HLA-A2 status
Number of subjects: 545
Study 29191595 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent pulsatile dacomitinib in Cohort A (EGFR T790M)
Number of subjects: 38
Study 29191595 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent pulsatile dacomitinib in Cohort B (unselected patients)
Number of subjects: 38
Study 29191595 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events from intermittent pulsatile dacomitinib
Number of subjects: 38
Study 29191814 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticipated partner notification (PN) practices
Number of subjects: 150
Study 29191814 — intervention group
Group type: EXPERIMENTAL
Intervention: Actual partner notification (PN) outcomes
Number of subjects: 150
Study 29191852 — intervention group
Group type: EXPERIMENTAL
Intervention: All patients in the CREST trial
Number of subjects: 2502
Study 29191916 — intervention group
Group type: EXPERIMENTAL
Intervention: Duvelisib 8 to 100 mg twice daily (MTD determined as 75 mg twice daily)
Number of subjects: 210